SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Kosan BioSciences -- KOSN -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (702)6/7/2006 11:36:08 AM
From: nigel bates  Read Replies (1) | Respond to of 933
 
Just a scenario, but if...

- Novartis succeeds in acquiring Neutec (v. likely)
- Mycograb (http://www.neutecpharma.com/mycograb.html) gets approved for fungal indications (pretty likely)
- Mycograb shows activity in cancer (who knows ?)

... then isn't off-label use going to make life more than a little tough for all the other Hsp90 compounds (particularly given Myco.'s relatively benign side effect profile) ?



To: keokalani'nui who wrote (702)6/9/2006 3:20:32 AM
From: mopgcw  Respond to of 933
 
i agree. i added another slug at these levels to my core position, for a trade.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News